Cemiplimab guided by ctDNA levels (PALACE)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, non-randomised, multicenter phase II trial enrolling 63 patients with stage IV or stage IIIB/C non-small cell lung cancer who have not received prior systemic therapy. All participants receive two cycles of cemiplimab, then have response assessment and ctDNA testing to guide whether they continue cemiplimab alone or add chemotherapy (carboplatin plus paclitaxel). The primary aim is to see whether using ctDNA to drive therapy decisions improves overall survival. The study includes about 2 years of treatment and 2 years of follow-up, conducted at several hospitals in Spain.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy
* PDL1 ≥50%
* ECOG performance status 0-1
* Patients aged ≥ 18 years
* Prior adjuvant or neoadjuvant chemotherapy for early stage is permitted if completed at least 6 months prior to enrolment
* Presence of at least one measurable lesion by CT-scan per RECIST version 1.1
* Anticipated life expectancy \>12 weeks
* Correct hematological, hepatic and renal function
* Patient consent must be obtained in the appropriate manner as established in the applicable local and regulatory requirements
* Patients must be accessible for treatment and follow-up
* Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 3 days before enrolment.
* All sexually active men and women of childbearing potential must use a highly effective contraceptive method during the study treatment and for a period of at least 4 months following the last administration of trial drugs

Exclusion Criteria:

* Patients whose tumors harbor an activating mutation in EGFR, ALK translocation, or ROS Proto-Oncogene 1 (ROS1) rearrangements sensitive to available targeted inhibitor therapy
* Patients with grade ≥2 neuropathy
* Pregnant or breastfeeding women
* Patients with a weight loss \>10% within the previous 3 months
* Patients with carcinomatous meningitis
* Patients with a history of other malignant diseases within the past 3 years
* Patients must have recovered from a major surgery at least 14 days prior to enrolment
* Patients with active or uncontrolled infections or with serious medical conditions or disorders that may not allow patient management as established in the protocol
* Prior treatment with antineoplasic drugs or thoracic radiotherapy for any reason different from the ones specific in the inclusion criteria
* Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease less than 6 months before enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy
* Patients with a combination of small cell lung cancer and non-small cell lung cancer, a carcinoid lung tumor or large cell neuroendocrine carcinoma
* Has known allergy or hypersensitivity to components of study drug
* Significant comorbidities that preclude the administration of chemotherapy according to the investigator's criteria
* Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments
* Untreated brain metastasis(es) that may be considered active
* Immunosuppressive corticosteroid doses within 4 weeks prior to the first dose of cemiplimab
* Uncontrolled infection with hepatitis B or hepatitis C or human immunodeficiency virus; or diagnosis of immunodeficiency
* History of interstitial lung disease or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.
* History of documented allergic reactions or acute hypersensitivity reactions attributed to antibody treatments
* Patients with a history of solid organ transplant
* Receipt of live vaccines within 30 days of first study treatment
* Women of childbearing potential, or sexually active men, who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment prior to the start of the first treatment, during the study, and for at least 4 months after the last dose.

Where it's running

• Hospital General de Alicante
  Alicante, Alicante, Spain Recruiting
• Hospital General de Elche
  Elche, Alicante, Spain Recruiting
• ICO Badalona, Hospital Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital Universitari Vall d' Hebron
  Barcelona, Barcelona, Spain Recruiting
• Hospital de la Santa Creu i Sant Pau
  Barcelona, Barcelona, Spain Recruiting
• ICO Hospitalet
  L'Hospitalet de Llobregat, Barcelona, Spain Recruiting

Study contacts

• Study coordinator: Eva Pereira
• Email: secretaria@gecp.org
• Phone: +34934302006

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early intervention strategies for lung cancer detection

  This study is testing if using low-dose CT scans in community health centers can help find lung cancer earlier in people aged 40-75 who don't have a history of the disease.

  Recruiting The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06988943

• Tarlatamab as maintenance treatment after chemo-radiotherapy for limited-stage small-cell lung cancer.

  This trial will test whether giving tarlatamab after chemo-radiotherapy helps people with limited-stage small-cell lung cancer stay progression-free longer.

  Recruiting at 20 sites Phase 2 Fundación GECP · Albacete, Albacete and 19 other locations · NCT07242547

• Teniposide after prior therapy for c-Myc–driven extensive-stage small cell lung cancer

  This will try teniposide in people with extensive-stage small cell lung cancer driven by high c-Myc who have progressed after standard treatment.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT06758700

• Infusion of IOV-4001 for advanced melanoma and lung cancer

  This study is testing a new treatment called IOV-4001 to see if it can help adults with advanced melanoma and lung cancer by targeting and killing their tumor cells.

  Recruiting at 10 sites Phase 1/2 Iovance Biotherapeutics, Inc. · Los Angeles, California and 10 other locations · NCT05361174

• New radiotherapy approach for advanced lung cancer

  This study is testing a new type of radiotherapy for patients with advanced lung cancer who can't have regular treatment to see if it can help them live longer and feel better.

  Recruiting Danish Lung Cancer Group · Aarhus · NCT03742687

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.